BMRN vs SRPT
BMRN: BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise. SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
Side-by-side fundamentals
| Metric | BMRN | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.40 | $15.82 | |
| Market cap as of 2026-07-23 | $11.3B | $1.7B | |
| P/E as of 2026-07-23 | 42.00 | 26.31 | SRPT lower |
| PEG as of 2026-07-23 | n/a | -23.53 | |
| Net margin as of 2026-07-23 | +8.3% | +3.0% | BMRN higher |
| Gross margin as of 2026-07-23 | +80.2% | +70.5% | BMRN higher |
| Operating margin as of 2026-07-23 | +9.7% | -1.1% | BMRN higher |
| ROE as of 2026-07-23 | +4.4% | +4.9% | SRPT higher |
| ROA as of 2026-07-23 | +3.4% | +1.9% | BMRN higher |
| Debt / equity as of 2026-07-23 | 0.23 | 0.56 | BMRN lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | -2.2% | BMRN higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +33.1% | SRPT higher |
| Beta as of 2026-07-23 | 0.23 | 0.19 | |
| 1-year return as of 2026-07-22 close | -1.4% | +16.2% | SRPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.